321 related articles for article (PubMed ID: 27815305)
1. TP53 Mutations in Breast and Ovarian Cancer.
Silwal-Pandit L; Langerød A; Børresen-Dale AL
Cold Spring Harb Perspect Med; 2017 Jan; 7(1):. PubMed ID: 27815305
[TBL] [Abstract][Full Text] [Related]
2. Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic TP53 mutations in noncancerous tissues.
Krimmel JD; Schmitt MW; Harrell MI; Agnew KJ; Kennedy SR; Emond MJ; Loeb LA; Swisher EM; Risques RA
Proc Natl Acad Sci U S A; 2016 May; 113(21):6005-10. PubMed ID: 27152024
[TBL] [Abstract][Full Text] [Related]
3. Genomic and transcriptomic plasticity in treatment-naive ovarian cancer.
Hoogstraat M; de Pagter MS; Cirkel GA; van Roosmalen MJ; Harkins TT; Duran K; Kreeftmeijer J; Renkens I; Witteveen PO; Lee CC; Nijman IJ; Guy T; van 't Slot R; Jonges TN; Lolkema MP; Koudijs MJ; Zweemer RP; Voest EE; Cuppen E; Kloosterman WP
Genome Res; 2014 Feb; 24(2):200-11. PubMed ID: 24221193
[TBL] [Abstract][Full Text] [Related]
4. Discovery of cancer common and specific driver gene sets.
Zhang J; Zhang S
Nucleic Acids Res; 2017 Jun; 45(10):e86. PubMed ID: 28168295
[TBL] [Abstract][Full Text] [Related]
5. A Comparative Analysis of Genetic and Epigenetic Events of Breast and Ovarian Cancer Related to Tumorigenesis.
Longacre M; Snyder NA; Housman G; Leary M; Lapinska K; Heerboth S; Willbanks A; Sarkar S
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27213343
[TBL] [Abstract][Full Text] [Related]
6. A living biobank of ovarian cancer ex vivo models reveals profound mitotic heterogeneity.
Nelson L; Tighe A; Golder A; Littler S; Bakker B; Moralli D; Murtuza Baker S; Donaldson IJ; Spierings DCJ; Wardenaar R; Neale B; Burghel GJ; Winter-Roach B; Edmondson R; Clamp AR; Jayson GC; Desai S; Green CM; Hayes A; Foijer F; Morgan RD; Taylor SS
Nat Commun; 2020 Feb; 11(1):822. PubMed ID: 32054838
[TBL] [Abstract][Full Text] [Related]
7. Breast Cancer Risk for Women With a
Li S; Hopper JL
JCO Precis Oncol; 2024 May; 8():e2400166. PubMed ID: 38820492
[TBL] [Abstract][Full Text] [Related]
8. Neoantigens in Ovarian Cancer: Embarrassment of Riches or Needles in a Haystack?
McNeish IA
Clin Cancer Res; 2018 Nov; 24(22):5493-5495. PubMed ID: 29980529
[TBL] [Abstract][Full Text] [Related]
9. Mutant p53 as a target for cancer treatment.
Duffy MJ; Synnott NC; Crown J
Eur J Cancer; 2017 Sep; 83():258-265. PubMed ID: 28756138
[TBL] [Abstract][Full Text] [Related]
10. Role of p53 Gene in Breast Cancer: Focus on Mutation Spectrum and Therapeutic Strategies.
Kaur RP; Vasudeva K; Kumar R; Munshi A
Curr Pharm Des; 2018; 24(30):3566-3575. PubMed ID: 30255744
[TBL] [Abstract][Full Text] [Related]
11. Clinical implications of germline mutations in breast cancer: TP53.
Schon K; Tischkowitz M
Breast Cancer Res Treat; 2018 Jan; 167(2):417-423. PubMed ID: 29039119
[TBL] [Abstract][Full Text] [Related]
12. Mutant p53 in breast cancer: potential as a therapeutic target and biomarker.
Duffy MJ; Synnott NC; Crown J
Breast Cancer Res Treat; 2018 Jul; 170(2):213-219. PubMed ID: 29564741
[TBL] [Abstract][Full Text] [Related]
13. High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints.
Lisio MA; Fu L; Goyeneche A; Gao ZH; Telleria C
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30813239
[TBL] [Abstract][Full Text] [Related]
14. Real-world evidence in the treatment of ovarian cancer.
Eisenhauer EA
Ann Oncol; 2017 Nov; 28(suppl_8):viii61-viii65. PubMed ID: 29232466
[TBL] [Abstract][Full Text] [Related]
15. Metabolic functions of the tumor suppressor p53: Implications in normal physiology, metabolic disorders, and cancer.
Lacroix M; Riscal R; Arena G; Linares LK; Le Cam L
Mol Metab; 2020 Mar; 33():2-22. PubMed ID: 31685430
[TBL] [Abstract][Full Text] [Related]
16. Ovarian Cancer Prevention and Screening.
Menon U; Karpinskyj C; Gentry-Maharaj A
Obstet Gynecol; 2018 May; 131(5):909-927. PubMed ID: 29630008
[TBL] [Abstract][Full Text] [Related]
17. The Association and Significance of p53 in Gynecologic Cancers: The Potential of Targeted Therapy.
Nakamura M; Obata T; Daikoku T; Fujiwara H
Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31689961
[TBL] [Abstract][Full Text] [Related]
18. Targeting mutant p53 for efficient cancer therapy.
Bykov VJN; Eriksson SE; Bianchi J; Wiman KG
Nat Rev Cancer; 2018 Feb; 18(2):89-102. PubMed ID: 29242642
[TBL] [Abstract][Full Text] [Related]
19. Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas.
Donehower LA; Soussi T; Korkut A; Liu Y; Schultz A; Cardenas M; Li X; Babur O; Hsu TK; Lichtarge O; Weinstein JN; Akbani R; Wheeler DA
Cell Rep; 2019 Jul; 28(5):1370-1384.e5. PubMed ID: 31365877
[TBL] [Abstract][Full Text] [Related]
20. New strategies in ovarian cancer treatment.
Lee JM; Minasian L; Kohn EC
Cancer; 2019 Dec; 125 Suppl 24(Suppl 24):4623-4629. PubMed ID: 31967682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
